Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
The stock options have an exercise price of $2.785 which is equal to the closing price of Taysha's common stock on the date of grant. Each stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of each stock option is subject to such employee's continued service to Taysha on each vesting date.
About Taysha Gene TherapiesTaysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company's management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact:Hayleigh Collins Senior Director, Corporate Communications and Investor RelationsTaysha Gene Therapies, Inc.hcollins@tayshagtx.com
Media Contact:Carolyn HawleyInizio EvokeCarolyn.hawley@inizioevoke.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
UPDATED - Aureus Greenway Holdings , Inc. Announces Twenty Six Million Dollar Private Placement Priced At-The Market under Nasdaq Rules
Kissimmee, FL, July 23, 2025 (GLOBE NEWSWIRE) -- Aureus Greenway Holdings Inc. (the 'Company', 'Aureus Greenway', 'we', 'us', 'our') (Nasdaq: AGH), an owner and operator of daily fee golf country clubs in the state of Florida, today announced that it has entered into definitive securities purchase agreements dated July 23, 2025 with accredited and institutional investors for the issuance and sale of units consisting of common stock (each a share of 'Common Stock') (or pre-funded warrants ('Pre-funded Warrants') to purchase in lieu thereof) together with common A warrants and common B warrants (each of the common A and common B warrants a "Common Warrant") to purchase the same number of shares of common stock (or Pre-funded Warrants) of the Company at a price of 0.87 per unit, on a brokered private placement basis, for aggregate gross proceeds of approximately $26 million, before deducting fees and offering expenses. The Company will be issuing a combination of 29,885,057, shares of common stock (or Pre-funded Warrants in lieu thereof), common warrants A to purchase 29,885,057 shares of common stock, and common warrants B to purchase 29,885,057 shares of common stock. Each Pre-funded Warrant will entitle the holder to acquire one share of common stock at an exercise price of $0.0001 per share, each common warrant A will be immediately exercisable and entitle the holder to acquire one share of common stock at an exercise price of $1.00 per share, for a period of five years following the closing of the Offering and each common warrant B will be immediately exercisable and entitle the holder to acquire one share of common stock at an exercise price of $1.25 per share, for a period of five years following the closing of the Offering. The private placement is expected to close on July 25, 2025, subject to customary closing conditions. The Company intends to use the proceeds from the offering for working capital and general corporate purposes. Revere Securities LLC and Dominari Securities LLC are acting as co- placement agents for the Offering. The securities offered and sold by the Company in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the "SEC") or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock and shares underlying the Pre-funded Warrants and Common Warrants to be issued in the private placement. Any resale of the Company's shares under such resale registration statement will be made only by means of a prospectus. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities will not be registered under the Securities Act or any state securities laws when issued at the closing of the private placement, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state laws. About Aureus Greenway Holdings Inc. Aureus Greenway Holdings Inc. (Nasdaq: AGH), owns and operates daily fee golf country clubs in the state of Florida that are designed to appeal to a wide-ranging population. The combination of our strategic locations and approachable golf-courses attracts both local and tourist demographics, allowing us to offer a variety of golf experiences while capturing a broad share of discretionary leisure spending. For more information, please visit our website at Forward-Looking Statements This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include predictions, expectations, estimates, and other information that might be considered future events or trends, not relating to historical matters. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Aureus Greenway's Annual Report on Form 10-K for the year ended December 31, 2024, and its periodic filings with the SEC provide a detailed discussion of these risks and uncertainties. There can be no assurance that Aureus Greenway will be able to complete the offering on the anticipated terms, or at all. Aureus Greenway does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, as required by law. Contact:Aureus Greenway Holdings Inc. aureus@
Yahoo
23 minutes ago
- Yahoo
Phoenix's Housing Market Unveiled: The "Twin Sword" of Skyrocketing Inventory Is Redefining 2025 – A Power Shift For Buyers, A Test For Sellers
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. The Phoenix housing market is cooling off rapidly after a post-pandemic boom, but it isn't all gloom and doom for metro real estate agents. In fact, Rosenbaum Realty Group in suburban Gilbert argues the 2025 market is perfectly fine and shifting into a long-needed balance between buyers and sellers. Of course, folks selling homes naturally shine the most attractive light on mixed data, even though it suggests lower income in the decade's second half. Phoenix's 1.6 million city residents translate into the fifth largest housing market in the U.S. while the surrounding metro raises that number to a healthy 4.8 million. City and metro housing inventory rose a whopping 54.3% year-over-year in the first quarter, with over 23,500 residences listed for sale. This marked a nine-year high for inventories, in which homes for sale surged 32% while new listings grew by 10.4%. Don't Miss: Accredited investors can —with up to 120% bonus shares—before this Uber-style disruption hits the public markets , which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum. Days on the market is tracking rapid inventory growth, rising to 53 days, which is slightly higher than the 51-day national average. However, it surged a whopping 20.5% in the last year, signaling a rapid slowdown. Other cities benefiting from the pandemic's "Zoom" migration are slowing down as well, particularly in Texas and Florida, so Phoenix's downtrend isn't surprising. The growing inventory gives potential buyers more leverage, as the agent notes, contributing to a 2.9% year-over-year price decline. Home prices have fallen almost 7% since the 2022 pandemic peak but Phoenix population continues to grow, with analysts forecasting another quarter million residents through 2026. This in-migration has led to predictions for moderate home price gains of 3.5% to 5.5% through the same period. Rosenbaum Realty sums up Phoenix's broad appeal, noting its "affordability compared to coastal metros like Los Angeles or San Francisco, with a cost of living only 6.3% above the national average. The agent also touts year-round sunshine, the diverse economy, including Intel (NASDAQ:INTC) and Taiwan Semiconductor Manufacturing (NYSE:TSM), and lifestyle amenities that appeal to residents fleeing higher-cost states. Trending: With Point, you can East Valley suburbs Mesa and Gilbert are the biggest losers in metro price depreciation so far, "down up to 15% in some segments," but the agency says "well-priced homes" are still selling at 98% of the listing price, on average. Even so, homeowners have lowered their asking prices in 31.3% of listings this year, highlighting a continued mismatch between the seller's optimism and the buyer's pessimism. Rosenbaum Realty also says it's an attractive housing market for investors, with average rents rising 1.2% year-over-year to $1,646 per month. Stubborn mortgage rates above 6% have lessened affordability, especially for first time buyers. But that's good news for investors who need to keep their rental properties full of paying customers. It also markets the city and metro as a "landlord-friendly regulatory environment with no rent control." Phoenix expects to add 60,833 new units by 2028, according to Rosenbaum Realty, but says that demand will continue to outstrip supply. This should slow or stop falling prices once buyers and sellers come into delicate balance. Of course, mortgage rates and the U.S. economy remain wild cards in this equation, with predictions for a recession that have yet to materialize. Read Next: This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Here's , starting today. Image: Shutterstock This article Phoenix's Housing Market Unveiled: The "Twin Sword" of Skyrocketing Inventory Is Redefining 2025 – A Power Shift For Buyers, A Test For Sellers originally appeared on
Yahoo
32 minutes ago
- Yahoo
ASP Isotopes Inc. Announces Pricing of $60 Million Underwritten Registered Direct Offering of Common Stock
WASHINGTON, July 23, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes' or the 'Company'), today announced the pricing of an underwritten registered direct offering of 7,500,000 shares of its common stock at a price of $8.00 per share to a single fundamental institutional investor. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $60.0 million. The offering is expected to close on or about July 25, 2025, subject to the satisfaction of customary closing conditions. Cantor and Canaccord Genuity acted as joint book-running managers for the offering. Ocean Wall Limited acted as financial advisor. The net proceeds of this offering are expected to be used for general corporate purposes, including working capital, operating expenses, and capital expenditures. The offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with and declared effective by the Securities and Exchange Commission ('SEC') and a related registration statement that was filed with the SEC pursuant to Rule 462(b) under the Securities Act of 1933 (and became automatically effective upon filing). This offering is being made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at When available, copies of the final prospectus supplement and accompanying prospectus relating to these securities may also be obtained by sending a request to: Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@ or Canaccord Genuity LLC, Attention: Syndication Department, 1 Post Office Square, 30th Floor, Boston, MA 02109, or by email at prospectus@ This press release does not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. About ASP Isotopes Inc. ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process ('ASP technology'). The Company's initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes). There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy applications. The ASP Technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass molecules. For more information, please visit Forward Looking Statements This press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements can be identified by words such as 'believes,' 'plans,' 'anticipates,' 'expects,' 'estimates,' 'projects,' 'will,' 'may,' 'might,' and words of a similar nature. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results, financial condition, and events may differ materially from those indicated in the forward-looking statements based upon a number of factors. Forward-looking statements are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Therefore, you should not rely on any of these forward-looking statements. There are many important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements, including: risks and uncertainties related to the satisfaction of customary closing conditions related to the public offering; the intended use of net proceeds from the public offering; the impact of general economic, industry or political conditions in the United States or internationally; the failure to obtain necessary regulatory approvals and third party consents for the proposed acquisition of Renergen; disruption from the proposed acquisition of Renergen making it more difficult to maintain business and operational relationships; significant transaction costs and unknown liabilities related to the proposed acquisition of Renergen; litigation or regulatory actions related to the proposed acquisition of Renergen; the outcomes of various strategies and projects undertaken by the Company; the potential impact of laws or government regulations or policies in South Africa, the United Kingdom or elsewhere; our reliance on the efforts of third parties; our ability to complete the proposed the construction and commissioning of our enrichment plant(s) or to commercialize isotopes using the ASP technology or the Quantum Enrichment Process; our ability to obtain regulatory approvals for the production and distribution of isotopes; the financial terms of any current and future commercial arrangements; our ability to complete certain transactions and realize anticipated benefits from acquisitions and contracts; dependence on our Intellectual Property (IP) rights, certain IP rights of third parties; the competitive nature of our industry; and the factors disclosed in Part I, Item 1A. 'Risk Factors' of the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and any amendments thereto and in the company's subsequent reports and filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise. No information in this press release should be interpreted as an indication of future success, revenues, results of operation, or stock price. All forward-looking statements herein are qualified by reference to the cautionary statements set forth herein and should not be relied upon. Contacts Jason Assad– Investor relationsEmail: Jassad@ 561-709-3043
